HomeBlog of Signaling Pathways

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Blog of Signaling Pathways

HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia

0 views | Nov 17 2022

Zhengchang He et al. thought that HO-1 could influence MDS resistance and progression to AML. [Read the Full Post]

Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC)

91 views | Nov 16 2022

Paulina Chmiel et al. thought that a central role in the development of BCC was played by the Hedgehog (Hh) signalling pathway. [Read the Full Post]

Multifunctional Polydopamine-Based Nanoparticles for Dual-Mode Imaging Guided Targeted Therapy of Lupus Nephritis

126 views | Nov 16 2022

Mifang Li et al. found that Nec-1/PDA@Pt-Fe3O4 nanocarrier exhibited good biocompatibility. [Read the Full Post]

THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours

32 views | Nov 15 2022

Jianyi Sun et al. demonstrated that CDK7 was relatively overexpressed in high-risk GISTs and predicted a poor outcome. [Read the Full Post]

Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy

113 views | Nov 15 2022

Zifan Feng et al. gave a systematic overview of the current status and characteristics of various approaches to developing the Hedgehog pathway inhibitors. [Read the Full Post]

CGRP protects bladder smooth muscle cells stimulated by high glucose through inhibiting p38 MAPK pathway in vitro

0 views | Nov 14 2022

Jun Xue et al. found that CGRP protected BSMCs from oxidative stress induced by HG in vitro, and inhibited the α-SM-actin expression decrease through inhibiting the intracellular p38 MAPK signaling pathway. [Read the Full Post]

Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells

100 views | Nov 14 2022

Sumeet Kaur et al. found that ricolinostat suppressed proliferation by inducing G2/M phase arrest and promoted apoptosis in cervical cancer cells, indicating that ricolinostat might be a promising antitumor agent in cervical cancer. [Read the Full Post]

Risk of cognitive impairment in men with advanced prostate cancer treated with novel hormonal agents: a systematic review and network meta-analysis

61 views | Nov 13 2022

Shi-Wei Huang et al. found that NHAs, especially enzalutamide, might increase the risk of cognitive impairment compared with placebo/standard care. [Read the Full Post]

c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer

39 views | Nov 13 2022

Martina Lepore Signorile et al. identified p38α as a promising therapeutic target, acting directly on c-MYC, with potential implications for countering c-MYC-mediated CRC proliferation, metastatic dissemination, and chemoresistance. [Read the Full Post]

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

74 views | Nov 12 2022

Iacopo Petrini et al. found that in combination with chemotherapy and lazertinib in NSCLCs who progressed on osimertinib (MARIPOSA-2). [Read the Full Post]

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer

0 views | Nov 12 2022

Jiyeon Yun et al. suggested that YH25448 is a promising third-generation EGFR inhibitor, which may be more effective and better tolerated than the currently approved osimertinib. [Read the Full Post]

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs

84 views | Nov 11 2022

Maan H Harbi et al. found that the Syk inhibitor R406 provided mild inhibition of platelet responses induced by atherosclerotic plaque and that this was mildly amplified by aspirin and ticagrelor. [Read the Full Post]

Dual Delivery of Cyclosporin A and Etodolac Using Polymeric Nanocapsules in a Rabbit Eye Model: Ocular Biodistribution and Pharmacokinetic Study

90 views | Nov 11 2022

Syed Nazrin Ruhina Rahman et al. thought that the biodistribution and pharmacokinetic data might help and strengthen their understanding of synergetic anti-inflammatory activity of CsA and Edc from nanocapsules after its ocular topical application for managing keratoconjunctivitis sicca. [Read the Full Post]

Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers

0 views | Nov 10 2022

Martin Gutierrez et al. found that the triplet combination of SNX-5422, carboplatin and paclitaxel followed by maintenance SNX-5422 therapy was well-tolerated and showed anti-tumor activity [Read the Full Post]

Hedgehog Signaling as a Therapeutic Target for Airway Remodeling and Inflammation in Allergic Asthma

90 views | Nov 10 2022

Anthony Tam et al. found that TGFβ1-induced airway remodeling was partially mediated through the hedgehog signaling pathway via the PTCH1-SMO-GLI axis. [Read the Full Post]

High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors

0 views | Nov 09 2022

Tatjana Ullmann et al. found that I-BET151 and HDAC inhibitors simultaneously upregulated the mRNA expression of pro-inflammatory IL-1ß. [Read the Full Post]

Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells

0 views | Nov 09 2022

Ria Goswami et al. found that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibited SARS-CoV-2 replication in vitro at a high selectivity index. [Read the Full Post]

Helicobacter pylori-infected human neutrophils exhibit impaired chemotaxis and a uropod retraction defect

43 views | Nov 08 2022

Allan Prichard et al. suggested that H. pylori inhibited the dynamic changes in myosin IIA contractility and front-to-back polarity that were essential for chemotaxis. [Read the Full Post]

Overexpression of bromodomain and extraterminal domain is associated with progression, metastasis and unfavorable outcome: highlighting prognostic and therapeutic value of BET protein family in gastric cancer

25 views | Nov 08 2022

Shahrzad Soleymani Fard et al. provided insights into the prognostic role of BET family in GC and proposed BET inhibition as a therapeutic strategy for GC patients. [Read the Full Post]

Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection

0 views | Nov 07 2022

Lydia E Hainley et al. thought that Chk1 inhibitors that were found to be safe and effective in clinical trials for cancer should be evaluated for antiviral activity against BKPyV. [Read the Full Post]